Targeted Therapies for Precision Oncology
Description
Cancer is a multifactorial disease with an increasingly high incidence. There are hundreds of different cancer types, defined by their anatomical location and molecular alterations, both of which influence oncogenesis and therapeutic response. The heterogeneity among tumors from different patients—as well as within a single patient’s tumor—poses a significant challenge to cancer treatment. It is essential to consider this heterogeneity in translational cancer research and in tailoring treatment regimens for patients. To achieve this, appropriate preclinical models that mimic the heterogeneity and dynamism of tumors are crucial, as they enable the development of therapeutic strategies aimed at advancing precision oncology. Our group aims to contribute to improving precision oncology, which seeks to select targeted therapies based on each patient’s molecular characteristics, focusing on those most likely to be effective for each individual.
Our main objectives are:
- Generation and characterization of new experimental models derived from patient tumors, both ex vivo and in vivo, to enhance precision oncology.
- Optimization of targeted therapies used in precision oncology by understanding the mechanisms of resistance, enabling the proposal of new therapeutic strategies that circumvent or delay such resistance.
- Identification and validation of predictive biomarkers of treatment response to improve the selection of personalized therapies for cancer patients.
- Study of new therapeutic targets and the mechanisms of action of novel therapeutic strategies aimed at advancing precision oncology.